美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

VanEck Biotech ETF

233.40

+2.230.96%

成交量：960

成交額：22.57萬

市值：4.68億

市盈率：- -

高：233.40

開：233.40

低：233.40

收：231.17

52周最高：244.35

52周最低：160.91

股本：200.65萬

流通股本：200.65萬

量比：0.61

換手率：0.05%

股息：0.95

股息率：0.41%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌

巴克萊上調安進目標價至380美元

Assembly股價上漲，因季度營收超出預期

庫利南股價上漲，因其肺癌藥物達到晚期臨床試驗目標

MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項

數據簡報-全球製藥企業斥資數十億以擴大在美業務

Tango因季度虧損額超出預期而股價下跌

Truist因Revolution Medicines在肺癌研發管線方面的潛力而上調其目標價

市值超4800億元的藥企股價漲逾4%: 這款「癌王」突破療法要來中國了

港股異動 | 百濟神州(06160)早盤升逾4% 與Revolution Medicines達成臨床合作將加快RAS賽道開發進展

百濟神州（06160）盤初漲3.94% 與安進聯合開發及商業化的安泰適正式投入臨床使用

百濟神州與Revolution Medicines達成臨床開發及區域商業化合作

百濟神州與Revolution Medicines宣佈合作；甘李藥業宣佈減肥新藥海外BD | 醫藥早參

每日经济新闻

美股異動 | 因競爭對手的藥物研發未達目標福泰製藥(VRTX.US)漲近7%

美股異動 | 因競爭對手的藥物研發未達目標福泰製藥(VRTX.US)漲近7%

福泰製藥(VRTX)股票8月10日開盤上漲9.76%：投資者必看的核心信息

TradingKey中文

數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額

Vertex Pharma股價上漲，因競爭對手的遺傳性疾病藥物研發遭遇挫折

GLP-1為王、專利懸崖逼近、新賽道搶跑跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

百濟神州獲Revolution Medicines四大資產在選定亞洲市場的獨家授權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BBH/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":233.4,"timestamp":1789660060642,"preClose":231.1734,"halted":0,"volume":960,"delay":0,"changeRate":0.009631730986350588,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"交易中","change":2.2266,"latestTime":"09-17 11:52:47 EDT","open":233.4,"high":233.4,"low":233.4,"amount":225665.1552,"amplitude":0,"askPrice":236.45,"askSize":300,"bidPrice":236.2,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":231.1734,"sharesOutstanding":1976503,"nav":230.79718,"aum":463095224.42,"dividendRate":0.004061,"bidAskSpread":0.001036,"preHourTrading":{"tag":"盘前","latestPrice":231.03,"preClose":231.1734,"latestTime":"08:23 EDT","volume":31,"amount":7162.073219999999,"timestamp":1789647809022,"change":-0.1434,"changeRate":-0.00062,"amplitude":0.00062},"postHourTrading":{"tag":"盘后","latestPrice":231.35,"preClose":231.1734,"latestTime":"19:30 EDT","volume":14,"amount":3236.4276,"timestamp":1789601405727,"change":0.1766,"changeRate":0.000764,"amplitude":0},"volumeRatio":0.605668,"impliedVol":0.2334,"impliedVolPercentile":0.8884},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.605668,"shares":2006503,"dividePrice":0.9478,"high":233.4,"amplitude":0,"preClose":231.1734,"low":233.4,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":233.4,"committee":-0.2,"eps":0,"divideRate":0.004061,"volume":960,"delay":0,"ttmEps":0,"open":233.4,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":228.6361,"twentyDayClose":244.0166,"sixtyDayClose":190.8296},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660848445","title":"EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848445","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848445?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:14","pubTimestamp":1786965255,"startTime":"0","endTime":"0","summary":"EyePoint公司未能证明Duravyu在保护视力方面不比Eylea明显逊色。而在接受Eylea治疗的患者中，未出现此类情况。EyePoint的股价在早盘交易中跌至4.16美元。EyePoint计划于2027年上半年向美国FDA提交批准申请，具体取决于预计于今年晚些时候公布的第二项晚期临床试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU2237438978.USD","IBBQ","LU2023250504.SGD","BBH","LU2106854487.HKD","BK4007","LU2468319806.SGD","TBXU","LU0320765992.SGD","IBB","LU2362540622.SGD","EYPT","LU0823434583.USD","LU0058720904.USD","LU2362541513.USD","LU0114720955.EUR","LU0889565916.HKD","LU0882574055.USD","BK4585","LU1974910355.USD","LU2089984988.USD","LU1917777945.USD","BK4139","LU0109394709.USD","OTLK","LU0289739699.SGD","LU2362541273.HKD","LU0823434740.USD","LU0823416689.USD","LU0053666078.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克萊上調安進目標價至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101358?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["UUP","TBXU","BBH","BK4588","LU2112291526.USD","BK4533","BK4566","AMGN","BK4585","IBBQ","BIB","PBE","LU1571399168.USD","LU1983299246.USD","LU0289739699.SGD","BK4534","BK4139","IE00BJT1NW94.SGD","LU1061106388.HKD","LU2242646821.SGD","SG9999001440.SGD","LU0058720904.USD","LU1057294990.SGD","LU0320765992.SGD","UDN","PJP","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0868494617.USD","LU1023059063.AUD","LU0889565916.HKD","IE0009355771.USD","BK4581","IE0002141913.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00B2B36J28.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","BK4599","LU2468319806.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659400001","title":"Assembly股價上漲，因季度營收超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2659400001","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659400001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 23:25","pubTimestamp":1786721141,"startTime":"0","endTime":"0","summary":"BUZZ-Assembly股价上涨，因季度营收超出预期8月14日-** 药物研发公司Assembly Biosciences（ASMB.O）股价上涨4.6%，报31.32美元** ASMB第二季度与吉利德（GILD.O）合作研究的收入为1340万美元，高于去年同期的960万美元** 据LSEG数据显示，分析师此前平均预期营收为860万美元** 公司表示，营收增长包括针对吉利德合作项目下未来活动最新预估所作的510万美元补足调整** 报告显示第二季度每股亏损20美分，而市场预期为每股亏损65美分** 计入当日涨幅后，该股年初至今累计上涨11.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4S44B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","ASMB","IBB","SG9999015952.SGD","LU0122379950.USD","LU1934455277.USD","LU2087621335.USD","BK4583","LU1037948541.HKD","LU0861579265.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU1066051498.USD","TBXU","TMED","GILD","BK4585","LU1585245621.USD","LU0965509101.SGD","LU0965509283.SGD","LU2468319806.SGD","LU1066053197.SGD","LU2324357040.USD","LU0234570918.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0965508806.USD","BK4139","LU0289739699.SGD","LU1037948897.HKD","BK4566","BMED","BK4588","BK4532","IE00BZ1G4Q59.USD","IBBQ","BK4578","BK4568","LU0114720955.EUR","IE00B19Z3B42.SGD","BK4550","LU0889565916.HKD","BBH","LU2112291526.USD","BIB","LU0109394709.USD","MEDI","SG9999015986.USD","LU1839511570.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659710130","title":"庫利南股價上漲，因其肺癌藥物達到晚期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2659710130","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659710130?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 17:40","pubTimestamp":1786614009,"startTime":"0","endTime":"0","summary":"BUZZ-库利南股价上涨，因其肺癌药物达到晚期临床试验目标8月13日-** 库利南治疗公司（Cullinan Therapeutics）CGEM.O的股价在盘前交易中上涨6%，至20.77美元** 库利南公司表示，其实验性抗癌药物zipalertinib与铂类化疗联合使用，在晚期临床试验中达到了改善无进展生存期的主要目标 (link)** 与单独化疗相比，该联合疗法显著延缓了既往未接受过治疗、携带","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4S44A0QI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","IE00B2B36J28.USD","IE00BJT1NW94.SGD","RVMD","CANC","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4139","LU0320765992.SGD","IDNA","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BBH","IE0002141913.USD","IE0009355771.USD","PTH","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658465479","title":"MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=2658465479","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658465479?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 05:18","pubTimestamp":1786483082,"startTime":"0","endTime":"0","summary":"BUZZ-MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项8月11日-** 药物开发商MacroGenics（MGNX.O）的股价在盘后交易中上涨3.8%，至4.07美元** 该公司表示，根据其与吉利德（GILD.O）就一项临床前双特异性项目（一种癌症疗法）达成的许可协议，已收到1000万美元的里程碑付款** 根据2022年签署的合作协议，MacroGenics与吉利德正在推进三个项目：处于临床阶段的抗癌疗法MGD024，以及两个处于临床前阶段的双特异性项目** MGNX仍有资格获得最高约16亿美元的额外开发、监管及商业里程碑付款** 今年以来，该公司股价已翻了一番多","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4481IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","LU1674673691.USD","BK4550","LU2087621335.USD","IBB","LU0965509101.SGD","BK4585","LU0234570918.USD","IE00B19Z3581.USD","MEDI","LU1934455863.HKD","LU1430594728.SGD","MGNX","IE00B7SZLL34.SGD","LU2089984988.USD","SG9999015978.USD","BIB","LU1839511570.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","TBXU","LU2468319806.SGD","LU0882574055.USD","LU1674673428.USD","LU2324357040.USD","BK4566","BMED","LU0114720955.EUR","LU0289739699.SGD","LU1571399168.USD","LU0058720904.USD","IE0002270589.USD","TMED","LU0965508806.USD","LU1778281490.HKD","LU1934455277.USD","IE00BSNM7G36.USD","IE00BKVL7J92.USD","LU1066051498.USD","BK4139","IBBQ","SG9999015945.SGD","SG9999015986.USD","BK4532","BBH","LU1585245621.USD","GILD","BK4588","BK4578","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658591102","title":"數據簡報-全球製藥企業斥資數十億以擴大在美業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2658591102","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658591102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:59","pubTimestamp":1786463961,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美业务更新了第18段中关于百健生产工厂的数据路透8月11日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。这家制药公司宣布将投资 6.5 亿美元 ，以扩大其位于波多黎各洪科斯工厂的药品生产规模，此举预计将创造近 750 个就业岗位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S448167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","SG9999015978.USD","LU1934455277.USD","LU2487616109.SGD","BK7067","LU1267930813.SGD","LU1804176565.USD","IE000WAW04H5.SGD","AZN","LU1201861249.SGD","LU2756315318.SGD","LU0965509010.AUD","LU2896262040.SGD","IE00B4JS1V06.HKD","LU2125909247.SGD","LU1037948897.HKD","LU2237443382.USD","LU0070217475.USD","LU0545562505.USD","LU1571399168.USD","LU0211331839.USD","BK4592","LU1868837300.USD","LU2592432038.USD","LU0320765992.SGD","LU0109394709.USD","LU2361044949.HKD","LU1989772840.SGD","BIB","BK4550","IE00BLSP4239.USD","SG9999001176.SGD","LU0511384066.AUD","LU1291159041.SGD","LU2129689605.HKD","BIIB","LU2265009873.SGD","AZNH","SG9999014906.USD","LU0058720904.USD","LU2468319806.SGD","LU0070302665.USD","CANC","SG9999003800.SGD","IE00B2B36J28.USD","LU2213496289.HKD","IE000MB6IJN5.SGD","ABBV","LU0158827948.USD","LU0823434583.USD","LU0237698245.USD","IE0001KFT4U8.USD","LU1323610961.USD","LU2125154778.USD","LU1093756168.USD","PBE","LU1941712264.USD","LU1551013425.SGD","LU2505996509.AUD","SG9999014880.SGD","LU0882574055.USD","TMED","LU0689472784.USD","IE0034235303.USD","LU2129689431.USD","LU0170899867.USD","BK4585","LU1914381329.SGD","LU2746668974.SGD","LU1023059063.AUD","LU0949170772.SGD","LU0097036916.USD","LU1720051017.SGD","GB00BDT5M118.USD","LU0994945656.USD","SGXZ57979304.SGD","LU0385154629.USD","LU1720051108.HKD","TRUH","SGXZ31699556.SGD","LU2133065610.SGD","BK7511","LU0306806265.USD","LU0471298694.HKD","LU0432979614.USD","IE00BFSS8Q28.SGD","IE0002141913.USD","LU2089283258.USD","IE00B1BXHZ80.USD","IE00B3PB1722.GBP","PJP","LU2430703178.SGD","LU0069063385.USD","IE000F7OJYX1.SGD","VHT","LU2750360997.AUD","LU0683600562.USD","OZEM","04332","LU0345770993.USD","THNR","LU2125909593.SGD","LU2491050071.SGD","LU1032955483.USD","IE00BGHQF631.EUR","XLV","LU0354030511.USD","LU1941712348.USD","LU1829250122.USD","PFE","SG9999014898.SGD","IBB","LU0057025933.USD","SG9999014914.USD","LU0211328371.USD","LU2433249047.HKD","LU0353189763.USD","LU1979441026.SGD","IE00BVYPNW00.USD","LU1670627923.USD","IE0004445015.USD","LU0786609619.USD","IE00BZ1G4Q59.USD","TBXU","IE0004445239.USD","BMY","SG9999015952.SGD","LU0787776722.HKD","LU2237438978.USD","LU2063271972.USD","LU2552382132.HKD","LU1551013342.USD","LU1839511570.USD","IE000BZT7R73.USD","IE00B7SZLL34.SGD","SGXZ99366536.SGD","LU2108987350.USD","LU1974910355.USD","LU2324357040.USD","SGXZ81514606.USD","SG9999014575.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","BK4583","LU0353189680.USD","LU0133085943.USD","SG9999014542.SGD","IE00BJLML261.HKD","IE00BSNM7G36.USD","LU2271345857.HKD","LLYZ","LU2361045086.USD","LU0256863811.USD","IE00B775H168.HKD","LU0477156953.USD","LU1064131342.USD","LU1066051811.HKD","LU1221951046.USD","LU1623119135.USD","LU2264538146.SGD","LU2087621335.USD","BK4532","LU1267930730.SGD","LU0943347566.SGD","LU0738911758.USD","SG9999014559.SGD","LU2357305700.SGD","LU2089284900.SGD","LU0203201768.USD","LU1366192091.USD","GILD","LU0310800379.SGD","LU1059921491.USD","LU0320765646.SGD","LU0234570918.USD","IE00BLSP4452.SGD","LU1929549753.HKD","LU0859254822.USD","LU1145028129.USD","LU1127390331.HKD","LU1868836591.USD","BK4566","BK4559","IE00BFTCPJ56.SGD","LU0198837287.USD","LU2023250843.SGD","BK4533","LU0985320562.USD","SG9999015945.SGD","LU0965509101.SGD","LU2491050154.USD","LU1917777945.USD","LU1778281490.HKD","LU2023251221.USD","LU2596442595.SGD","LU1732799900.SGD","RXL","BBH","PPH","IE00BVYPNV92.GBP","LU2430703251.USD","BK4534","LU2456880835.USD","LU0912757837.SGD","SGXZ80539844.SGD","LU1506573853.SGD","LU0210528500.USD","PAWZ","LU0861579265.USD","LU2471134796.USD","LU2505996681.GBP","IE00BJJMRZ35.SGD","LU2471134952.CNY","IE00B19Z9P08.USD","LU0456855351.SGD","LU0882574139.USD","LU2237443895.HKD","LU2125154935.USD","LLYX","LU0265550946.USD","LU1670710661.SGD","LU0094547139.USD","LU0795875169.SGD","IE00B42XCP33.USD","LU2746668461.USD","LU0426412945.USD","LU2211815571.USD","LU2089984988.USD","LU1496350171.SGD","LU0114720955.EUR","LU1244550221.USD","AMGN","LU0053666078.USD","LLY","LU1934455194.USD","IE00B4R5TH58.HKD","LU0208291251.USD","LU2471134523.USD","LU0203345920.USD","LU1883839398.USD","SG9999015341.SGD","IE00B19Z9Z06.USD","LU1043141396.HKD","LU2023250504.SGD","CURE","LU0238689110.USD","LU2112291526.USD","WDNA","IE0002270589.USD","LU1066053197.SGD","IE0000B7K699.USD","CSL.AU","IBBQ","LU0553294199.USD","LU0726765562.USD","LU0545039389.USD","LU1935042991.SGD","LU1116320901.HKD","LU1868837136.USD","LU0980610538.SGD","LU0708994859.HKD","IE00BFSS7M15.SGD","LU0661504455.SGD","LU0417517546.SGD","FTXH","LU0320765059.SGD","MEDX","LU0289739343.SGD","IE00BDGV0183.EUR","LU2462157665.USD","LU2357627491.SGD","LU0889566641.SGD","LU1699723380.USD","LU0471298777.SGD","LU0128525929.USD","LU1674673691.USD","GLAM","LU1670711123.USD","HRTS","IE00B7KXQ091.USD","LU0106261372.USD","LU1670711040.USD","LU0472753341.HKD","SG9999001440.SGD","IE00BFXG1179.USD","LU1989772923.USD","LU0316494557.USD","LU2237443978.SGD","LU1280957306.USD","SG9999018857.SGD","IE00BN29S564.USD","LU1221951129.SGD","LU1162221912.USD","IXJ","IE00BKDWB100.SGD","LU1121112475.USD","LU0689626769.HKD","SG9999001176.USD","BK7508","LU0267386448.USD","AGNG","LU0985481810.HKD","IE00BKPKM429.USD","LU1934455863.HKD","LU0823434740.USD","LU2236285917.USD","LU1430594728.SGD","LU1267930490.SGD","LU1066051225.USD","LU2750360641.GBP","LU1712237335.SGD","JNJ","LU1032466523.USD","LU1035775433.USD","LU1988902786.USD","LU2087625088.SGD","LU0130517989.USD","LU1894683264.USD","LU0225771236.USD","LU2403377893.USD","IE0009355771.USD","LU2360106947.USD","LU2028103732.USD","LU0158827781.USD","BK4599","IE00BK4W5L77.USD","LU1989771016.USD","LU2552382215.SGD","BK4568","LU2168564149.EUR","LU2417539215.USD","LU0708995401.HKD","MRK","IYH","IE00BJT1NW94.SGD","SG9999014567.USD","LU1003077747.HKD","LU1629891620.HKD","LU2462591350.SGD","LU2168564495.EUR","LU1035773651.USD","ELIL","LU1228905540.USD","MEDI","LU0345769631.USD","LU0203347892.USD","SG9999011175.SGD","LU0266013472.USD","SG9999018865.SGD","LU0124676726.USD","BK7501","LU0211327993.USD","SG9999015986.USD","LU0225284248.USD","LU0640476718.USD","SG9999017495.SGD","LU0130102774.USD","LU2461242641.AUD","LU0109391861.USD","LU0265550359.USD","LU0234572021.USD","LU0426417589.USD","LU0321505439.SGD","LU0162691827.USD","SG9999015358.SGD","IE00BJJMRX11.SGD","LU1267930573.SGD","LU2237443622.USD","LU1093756325.SGD","LU0792757196.USD","LU2552382058.USD","LU0965509283.SGD","LU0889565916.HKD","LU0320765489.SGD","ILDR","LU2602419157.SGD","LU1983299246.USD","LU1037948541.HKD","LU0203202063.USD","MHIP","LU2129689514.USD","LU0820561818.USD","LU2360032135.SGD","LU1261432733.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU1894683348.USD","LU0345769128.USD","LU1232071149.USD","LU2347655073.USD","IE00B19Z3581.USD","LU0072461881.USD","LU2237443549.SGD","LU1732800096.USD","LU0354030438.USD","GDOC","LU1585245621.USD","LLII","LU0795875086.SGD","LU0868494708.USD","IE00BN8TJ469.HKD","LU0310799852.SGD","LU0942090050.USD","LU0289961442.SGD","LU1244550494.USD","LU0225283273.USD","LU1069344957.HKD","SGXZ51526630.SGD","LU1814569148.SGD","LU0029864427.USD","LU1718418525.SGD","BK4516","IE00B1XK9C88.USD","LU0466842654.USD","LU0345770308.USD","LU0868494617.USD","LU1496350502.SGD","LU2756315664.SGD","LU0323591593.USD","IE00BK4W5M84.HKD","IE00BBT3K403.USD","IE00BJJMRY28.SGD","LU1670710588.SGD","LU2491049909.HKD","LU1057294990.SGD","LU0648001328.SGD","LU1066051498.USD","SG9999002232.USD","JDOC","LU0672654240.SGD","LU1043141123.HKD","SG9999002224.SGD","IE00B894F039.SGD","IE000SO60NU8.SGD","BK4504","BMED","LU1074936037.SGD","LU0823416689.USD","LU1670628061.USD","LU1548497426.USD","LU0079474960.USD","LU2471134879.HKD","LU1228905037.USD","LU1674673428.USD","LU0006306889.USD","LU2111349929.HKD","LU0820562030.AUD","LU0306807586.USD","LU2168563687.JPY","IHE","LU2237443465.HKD","LU0964807845.USD","LU0098860793.USD","LU1244550577.SGD","LU0061475181.USD","LU0096364046.USD","LU2430703095.HKD","ELIS","BK4578","IE00BKVL7J92.USD","LU2347655156.SGD","LU0256863902.USD","LU1923622614.USD","LU2023250330.USD","LU0210536198.USD","BK4007","FHLC","LU1061106388.HKD","LU1868836914.USD","LU0174119429.USD","LU2361044865.SGD","IE0005OL40V9.USD","LU1069347547.HKD","IE00BWXC8680.SGD","LU0122379950.USD","SG9999013999.USD","BK4139","LU1868836757.USD","LU2168564222.USD","BK4588","LU0321505868.SGD","LU0820561909.HKD","LU1196500208.SGD","LU0965508806.USD","LU2242652126.USD","BK4581","LU1116320737.USD","LU0395794307.EUR","LU2168564065.EUR","LU2106854487.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658391156","title":"Tango因季度虧損額超出預期而股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658391156","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658391156?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:19","pubTimestamp":1786461555,"startTime":"0","endTime":"0","summary":"BUZZ-Tango因季度亏损额超出预期而股价下跌8月11日-** 药物研发公司Tango TherapeuticsTNGX.O股价下跌3.3%，报26.75美元** 据LSEG数据显示，该公司报告第二季度每股亏损37美分，而分析师平均预期为每股亏损31美分** TNGX报告称，截至2026年6月30日的三个月内未产生合作收入，原因是与吉利德GILD.O的合作关系及研发活动已终止** 该公司202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4T44814U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","IE00B4R5TH58.HKD","GILD","LU2087621335.USD","LU0289739699.SGD","IE0009355771.USD","IE0002270589.USD","BK4139","LU0320765992.SGD","PTH","LU0114720955.EUR","BK4585","BK4532","IE00BJJMRZ35.SGD","IE00B7SZLL34.SGD","LU1066051498.USD","BK4588","LU2089984988.USD","SG9999015952.SGD","CANC","LU1778281490.HKD","LU1066053197.SGD","MEDI","LU0109394709.USD","LU1934455277.USD","TBXU","IBBQ","BIB","IE00B2B36J28.USD","LU1674673691.USD","IE00B19Z3581.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU0889565916.HKD","LU2324357040.USD","BBH","LU1934455863.HKD","LU1674673428.USD","IBB","IDNA","BK4583","BMED","LU0965508806.USD","TMED","TNGX","LU2468319806.SGD","LU1037948897.HKD","RVMD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975709","title":"Truist因Revolution Medicines在肺癌研發管線方面的潛力而上調其目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975709","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975709?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 19:42","pubTimestamp":1786448532,"startTime":"0","endTime":"0","summary":"BUZZ-Truist因Revolution Medicines在肺癌研发管线方面的潜力而上调其目标价8月11日-** 券商Truist Securities将Revolution Medicines（RVMD.O）的目标股价从210美元上调至231美元** 维持“买入”评级** 指出elironrasib和zoldonrasib近期已推进至一线非小细胞肺癌（NSCLC）的晚期临床试验，这进一步巩","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4480SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4139","IE00BFTCPJ56.SGD","LU0889565916.HKD","RVMD","IE0009355771.USD","LU0320765992.SGD","IDNA","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0109394709.USD","CANC","IE0009354923.USD","PTH","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800億元的藥企股價漲逾4%: 這款「癌王」突破療法要來中國了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658161961?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","LU2360107325.USD","BK4588","IE0009354923.USD","BK4141","IDNA","IE00B2B36J28.USD","LU0348723411.USD","LU0588546209.SGD","LU2357305700.SGD","BK4585","KURE","LU0320765992.SGD","LU1720051017.SGD","BK1588","LU1861215975.USD","IE00BJT1NW94.SGD","LU1861214812.USD","IE00BFMHRM44.USD","PTH","BK4605","LU0724618433.USD","LU1861219969.SGD","LU1548497426.USD","ON","LU1983260115.SGD","RVMD","LU1854104046.USD","BK4512","LU0889565916.HKD","LU1720051108.HKD","LU1978683503.SGD","LU2298322129.HKD","LU0109394709.USD","688235","BK1583","BBH","06160","IE00BJJMRZ35.SGD","LU0124384867.USD","LU1251922891.USD","IE0009355771.USD","IE00BZ199S13.USD","IE00BD6J9T35.USD","LU1770034418.SGD","LU1854103824.USD","BK0239","BK4139","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股異動 | 百濟神州(06160)早盤升逾4% 與Revolution Medicines達成臨床合作 將加快RAS賽道開發進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658965691?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0228659784.USD","BBH","BK1500","LU0109394709.USD","BK0239","LU0588546209.SGD","LU0307460666.USD","LU1770034418.SGD","688235","ONC","BK4526","IE00B2B36J28.USD","LU0828237510.HKD","BK4139","IDNA","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","VXUS","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU2328871848.SGD","BK1161","LU0889565916.HKD","KURE","LU1719994722.HKD","PTH","LU1251922891.USD","LU0320765992.SGD","BK4585","IE0009354923.USD","LU1969619763.USD","IE0002141913.USD","RVMD","LU1303224171.USD","CANC","BK1588","BK1583","KCAI","06160","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百濟神州（06160）盤初漲3.94% 與安進聯合開發及商業化的安泰適正式投入臨床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196566?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160","IE00B4R5TH58.HKD","LU1571399168.USD","LU0058720904.USD","LU1770034418.SGD","LU0109394709.USD","BK1588","LU0122379950.USD","LU0828237510.HKD","IE00BJT1NW94.SGD","LU0228659784.USD","AMGN","IBBQ","LU0289739699.SGD","BK4139","IE00B2B36J28.USD","SG9999001440.SGD","BBH","PJP","KURE","BK1500","IBB","TBXU","IE0009355771.USD","LU0588546209.SGD","BK1161","LU1061106388.HKD","BK4533","LU0307460666.USD","LU2242646821.SGD","LU2112291526.USD","688235","IE0002141913.USD","PBE","BK1583","BK4588","LU1983299246.USD","BK4534","BK4566","LU1057294990.SGD","LU1969619763.USD","BIB","BK4526","BK4599","LU1023059063.AUD","BK4585","LU2089984988.USD","LU2468319806.SGD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950149","title":"百濟神州與Revolution Medicines達成臨床開發及區域商業化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950149?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 07:40","pubTimestamp":1786405224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","LU0109394709.USD","ONC","BK4526","IE00B2B36J28.USD","BK4139","IDNA","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","PTH","LU0320765992.SGD","BK4585","IE0009354923.USD","IE0002141913.USD","RVMD","CANC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百濟神州與Revolution Medicines宣佈合作；甘李藥業宣佈減肥新藥海外BD | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","LU0307460666.USD","LU1969619763.USD","IE00B2B36J28.USD","ONC","LU0228659784.USD","LU1719994722.HKD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK0239","BK1515","LU0588546209.SGD","BK1588","BK4139","IDNA","PTH","IE0009354923.USD","LU2328871848.SGD","LU0828237510.HKD","BK4585","06160","BBH","CANC","IE0002141913.USD","RVMD","603087","IE00B4R5TH58.HKD","LU0320765992.SGD","BK1583","IE00BJJMRZ35.SGD","BK1574","09939","BK4526","BK1161","LU0109394709.USD","LU1303224171.USD","BK1500","LU1251922891.USD","BK4588","688235","BD","LU1770034418.SGD","159938","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930620","title":"美股異動 | 因競爭對手的藥物研發未達目標 福泰製藥(VRTX.US)漲近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658930620?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ9MQY76.HKD","LU0256863811.USD","LU0320765992.SGD","LU2362541513.USD","LU0417517546.SGD","LU1674673691.USD","LU1674673428.USD","VRTX","LU2417539215.USD","IE00BFTCPJ56.SGD","LU1069344957.HKD","SG9999001176.USD","LU1778281490.HKD","IBBQ","LU1035775433.USD","LU1430594728.SGD","LU1093756168.USD","TBXU","BK4139","IBB","IE0002270589.USD","LU2089984988.USD","LU2236285917.USD","SG9999001176.SGD","IDNA","BBH","PBE","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BIB","SG9999013999.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","BK4567","LU2462157665.USD","LU0289739699.SGD","LU0058720904.USD","GNMX","LU1585245621.USD","IBBJ","IE00B19Z3581.USD","LU0234570918.USD","LU2362540622.SGD","BK4585","BK4588","LU0889565916.HKD","IE0009355771.USD","LU2456880835.USD","IE0002141913.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793062","title":"美股異動 | 因競爭對手的藥物研發未達目標 福泰製藥(VRTX.US)漲近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658793062?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，$福泰制药(VRTX)$(VRTX.US)早盘涨近7%，创历史新高;而竞争对手$Sionna Therapeutics(SION)$(SION.US)暴跌超90%，创记录新低。消息面上，SION表示，由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标，公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁，但此次试验失败消除了这一担忧。VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病，会导致肺部进行性损伤。","market":"us","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478244.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SGXZ57979304.SGD","LU0417517546.SGD","BIB","GNMX","PBE","LU1674673428.USD","IE00B2B36J28.USD","LU1430594728.SGD","LU0061475181.USD","LU2456880835.USD","IE00BJT1NW94.SGD","LU0256863811.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","IE00B19Z9P08.USD","BK4567","IE00B894F039.SGD","LU1585245621.USD","LU2236285917.USD","LU2462157665.USD","VRTX","BK4139","LU2468319806.SGD","IDNA","LU1674673691.USD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","IBB","BBH","LU0079474960.USD","SG9999001176.USD","LU0058720904.USD","IE0002141913.USD","IE00BZ9MQY76.HKD","TBXU","IE00B4R5TH58.HKD","LU0320765992.SGD","SG9999001176.SGD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU0234570918.USD","LU0109394709.USD","BK4532","IE00B19Z3581.USD","LU1778281490.HKD","LU2417539215.USD","IBBJ","IBBQ","LU2362541273.HKD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658934147","title":"福泰製藥(VRTX)股票8月10日開盤上漲9.76%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2658934147","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658934147?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:48","pubTimestamp":1786369694,"startTime":"0","endTime":"0","summary":"• 福泰制药（Vertex）公布了其非阿片类疼痛治疗候选药物的积极III期临床数据。\n• 在产品于国际市场成功上市后，该公司上调了全年营收指引。\n• 分析师维持“买入”评级，平均目标价为557.64美元。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262092811-market-movers-vrtx-20260810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","LU1778281490.HKD","LU2462157665.USD","LU2456880835.USD","LU2362540622.SGD","VRTX","TBXU","BBH","BK4567","BK4588","LU2362541513.USD","BK4533","BK4585","IE00B19Z3581.USD","IBBQ","IDNA","BIB","PBE","LU1585245621.USD","SG9999001176.SGD","SG9999001176.USD","IE0002270589.USD","IE00B19Z9Z06.USD","BK4139","IE00BJT1NW94.SGD","LU0256863811.USD","LU0432979614.USD","LU0058720904.USD","LU2237438978.USD","LU2324357040.USD","BK4532","LU0320765992.SGD","IE00BZ9MQY76.HKD","LU1035775433.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","LU0234570918.USD","LU0823416689.USD","LU0061475181.USD","IE0002141913.USD","IE00B4R5TH58.HKD","LU2089984988.USD","LU2236285917.USD","LU1093756325.SGD","LU1430594728.SGD","SG9999013999.USD","LU2362541273.HKD","LU1093756168.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931998","title":"數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931998","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931998?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:18","pubTimestamp":1786367928,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美国的市场份额修改发稿日期，补充百时美施贵宝的投资计划路透8月10日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。赛诺菲计划通过直接投资公司现有基地以及与其他国内制造商建立合作伙伴关系，扩大其在美国的生产能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4T4470YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","IE00B42XCP33.USD","LLY","LU0980610538.SGD","LU2471134879.HKD","CANC","LU0210528500.USD","LU0882574139.USD","IYH","LU1003077747.HKD","LU1267930573.SGD","LU2471134523.USD","BK4599","LU0868494708.USD","LU1839511570.USD","LU0210536198.USD","LU1974910355.USD","BK4504","LU1066051811.HKD","LU0203347892.USD","LU0320765646.SGD","LU0265550359.USD","LU2746668974.SGD","IE00B19Z9Z06.USD","LU0198837287.USD","LU0130517989.USD","LU0162691827.USD","IE0004445239.USD","LU0310800379.SGD","LU0689626769.HKD","LU2129689605.HKD","LU0345769128.USD","LU1261432733.SGD","BK7067","LU0154236417.USD","LU1032955483.USD","LU2750360641.GBP","LU0203201768.USD","LU1280957306.USD","LU1496350502.SGD","LU2028103732.USD","BK4592","LU2360032135.SGD","IE0034235303.USD","LU2213496289.HKD","LU1232071149.USD","LU1323610961.USD","LU0106261372.USD","LU1934455277.USD","LU1868836757.USD","SG9999003800.SGD","LU0395794307.EUR","LU0211328371.USD","LU2357305700.SGD","BBH","IBBQ","LU1585245621.USD","NVO","SG9999015986.USD","LU2237443895.HKD","LU1623119135.USD","LU2023250330.USD","LU2087621335.USD","LLYX","LU1941712264.USD","IE0002141913.USD","IE00BVYPNW00.USD","LU2089984988.USD","LU2896262040.SGD","LU0964807845.USD","LU1670627923.USD","LU0203345920.USD","IE00BN8TJ469.HKD","LU0471298694.HKD","LU1032466523.USD","LU1267930730.SGD","IE00B775H168.HKD","IE00BWXC8680.SGD","LU0237698245.USD","VHT","GILD","LU1670711040.USD","BK4534","IE00BFTCPJ56.SGD","LU2106854487.HKD","BK4588","LU0234570918.USD","IE00BFSS8Q28.SGD","LU0943347566.SGD","LU1934455863.HKD","LU2505996681.GBP","LU2552382058.USD","RXL","LU1244550221.USD","LU0683600562.USD","SG9999014880.SGD","LU0823434583.USD","LU1043141123.HKD","LU2430703095.HKD","PJP","SG9999014567.USD","LU0553294199.USD","BK4559","LU2361044865.SGD","LU2237443465.HKD","LU0289739699.SGD","LU1935042991.SGD","LU0098860793.USD","LU1116320737.USD","LU0345769631.USD","LU1366192091.USD","LU0128525929.USD","IE00BJT1NW94.SGD","LU1868836591.USD","IE00B2B36J28.USD","LU0174119429.USD","IE0005OL40V9.USD","LU2361045086.USD","SGXZ81514606.USD","BK7511","LU1868837300.USD","LU0320765489.SGD","LU0471298777.SGD","LU0889566641.SGD","IE000MB6IJN5.SGD","ELIL","LU0321505439.SGD","LU0456855351.SGD","CSL.AU","LU1983299246.USD","GSK.UK","SG9999015341.SGD","LU0432979614.USD","LU0859254822.USD","LU0267386448.USD","LU1814569148.SGD","LU1551013425.SGD","LU2347655073.USD","SGXZ80539844.SGD","LU2264538146.SGD","LU1196500208.SGD","LU1914381329.SGD","LU2089284900.SGD","LU2756315664.SGD","LU1989771016.USD","LU1934455194.USD","LU0823434740.USD","LU0820561909.HKD","LU1066051498.USD","IE0004445015.USD","FHLC","LU2242652126.USD","LU2211815571.USD","LU2750360997.AUD","LU2023250843.SGD","LU2324357040.USD","BK4566","LU2361044949.HKD","LU1035773651.USD","LU1244550494.USD","LU2237443978.SGD","BK4532","SG9999015358.SGD","LU0786609619.USD","BMED","LU0726765562.USD","LU0316494557.USD","LU1069347547.HKD","IE00BK4W5M84.HKD","BK4585","LU0545039389.USD","SG9999014906.USD","LU1829250122.USD","IE0009355771.USD","LU2491050071.SGD","SGXZ51526630.SGD","LU0787776722.HKD","IE00BKVL7J92.USD","IE00B19Z9P08.USD","LU1267930490.SGD","LU1291159041.SGD","IE00BGHQF631.EUR","LU1804176565.USD","LU1037948541.HKD","PAWZ","LU0820562030.AUD","LU2125154935.USD","LU2471134796.USD","LU1929549753.HKD","LU2602419157.SGD","LU1023059063.AUD","LU0511384066.AUD","LU0320765992.SGD","LU1093756325.SGD","LU1732799900.SGD","SG9999014914.USD","ELIS","LU1069344957.HKD","LU1496350171.SGD","LU0130102774.USD","IE000F7OJYX1.SGD","PFE","SG9999014559.SGD","MEDI","LU0310799852.SGD","LU0094547139.USD","HRTS","SGXZ57979304.SGD","IXJ","LU1066051225.USD","LU0321505868.SGD","LU2237443622.USD","LU0648001328.SGD","LU1037948897.HKD","LU2456880835.USD","TMED","LU0225283273.USD","LU0208291251.USD","IE00B19Z3B42.SGD","LU1221951129.SGD","IE00B7SZLL34.SGD","ILDR","LU0708995401.HKD","LU2133065610.SGD","LU2108987350.USD","LU2430703251.USD","LU0256863811.USD","IE0002270589.USD","LU0985320562.USD","LU1778281490.HKD","LU0096364046.USD","BK7508","LU1059921491.USD","LU0057025933.USD","LU0170899867.USD","MEDX","LU2471134952.CNY","LU0994945656.USD","LU1718418525.SGD","LU0070217475.USD","IE00B3PB1722.GBP","LU1057294990.SGD","LU0306806265.USD","LU0689472784.USD","JDOC","LU2596442595.SGD","LU0109391861.USD","LU1720051108.HKD","SG9999011175.SGD","LU0124676726.USD","LU1035775433.USD","LU2552382132.HKD","GSK","LU2491049909.HKD","LU0266013472.USD","SG9999014575.USD","LU0545562505.USD","LU0158827948.USD","LU2265009873.SGD","SG9999018865.SGD","LU1868836914.USD","IE000BZT7R73.USD","LU0792757196.USD","LU0417517546.SGD","LU0477156953.USD","LU1720051017.SGD","LU1116320901.HKD","SG9999013999.USD","SGXZ31699556.SGD","LU2552382215.SGD","LU1548497426.USD","LU1670710588.SGD","SG9999001440.SGD","LU2168564222.USD","LU0795875169.SGD","LU2089283258.USD","LU0323591593.USD","LU2242646821.SGD","IE00BK4W5L77.USD","IE00B3T34201.USD","LU0238689110.USD","SG9999014542.SGD","LU0353189680.USD","FTXH","LU2756315318.SGD","BK4568","IE00BN29S564.USD","IE00BJJMRX11.SGD","LU0640476718.USD","LU2125909247.SGD","LU2462591350.SGD","LU2491050154.USD","LU1145028129.USD","LU0353189763.USD","LU1732800096.USD","IE000M9KFDE8.USD","SGXZ99366536.SGD","BK4550","LU0122379950.USD","LU0965509283.SGD","LU1043141396.HKD","LU0203202063.USD","LU2347655156.SGD","SG9999002232.USD","LU0097036916.USD","LU0354030511.USD","LU2237443382.USD","SG9999017495.SGD","IE00BDGV0183.EUR","LU0912757837.SGD","LU2112291526.USD","LU0354030438.USD","ABBV","LU1629891620.HKD","NVOX","IE00BVYPNV92.GBP","LU1989772840.SGD","LU2592432038.USD","LU1674673428.USD","LU0385154629.USD","IE00BJJMRY28.SGD","IE00B1BXHZ80.USD","LU2087625088.SGD","THNR","LU0079474960.USD","SG9999002224.SGD","MHIP","LU0345770993.USD","LU1074936037.SGD","LU0882574055.USD","LU0211327993.USD","LU1571399168.USD","LU2129689514.USD","LU0306807586.USD","LU0949170772.SGD","LU1868837136.USD","LU0053666078.USD","LU0109394709.USD","LLII","LU0058720904.USD","LU0861579265.USD","GSKH","IBB","LU1228905037.USD","PPH","LU0061475181.USD","LU0289961442.SGD","SG9999001176.USD","LU1121112475.USD","LU1941712348.USD","PBE","LU2237443549.SGD","LU0889565916.HKD","LU2236285917.USD","LLYZ","LU2505996509.AUD","LU2168564065.EUR","LU1674673691.USD","AGNG","BIIB","LU1221951046.USD","LU0029864427.USD","LU0985481810.HKD","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","IE00BBT3K403.USD","LU2468319806.SGD","IE000SO60NU8.SGD","IE00B4JS1V06.HKD","LU1699723380.USD","XLV","LU0661504455.SGD","IE00BJJMRZ35.SGD","LU1228905540.USD","IE00BKPKM429.USD","LU1267930813.SGD","LU1244550577.SGD","SG9999001176.SGD","JNJ","LU1670710661.SGD","IE00BKDWB100.SGD","LU0256863902.USD","IE00B19Z3581.USD","LU2357627491.SGD","LU2746668461.USD","IE00BSNM7G36.USD","LU2168564149.EUR","LU2023251221.USD","LU0225284248.USD","LU0426417589.USD","LU2487616109.SGD","AZNH","LU1127390331.HKD","LU0211331839.USD","LU2063271972.USD","IE00B1XK9C88.USD","LU2125909593.SGD","LU1201861249.SGD","LU0965508806.USD","LU0426412945.USD","LU2403377893.USD","LU0795875086.SGD","LU1894683264.USD","LU2023250504.SGD","LU2111349929.HKD","LU1506573853.SGD","LU2430703178.SGD","GLAM","IE00BLSP4239.USD","IE00BJLML261.HKD","LU1670711123.USD","LU0708994859.HKD","LU2125154778.USD","LU0965509101.SGD","SG9999015978.USD","LU1917777945.USD","BK4139","SG9999015952.SGD","LU1989772923.USD","LU0234572021.USD","LU1894683348.USD","BIB","LU1712237335.SGD","IHE","LU2168563687.JPY","LU2360106947.USD","BMY","IE00BFSS7M15.SGD","IE00BLSP4452.SGD","LU0823416689.USD","LU1093756168.USD","AMGN","LU1430594728.SGD","BK4583","IE000WAW04H5.SGD","LU0868494617.USD","LU0069063385.USD","LU1883839398.USD","LU2417539215.USD","LU1162221912.USD","LU0225771236.USD","LU0466842654.USD","LU0820561818.USD","LU0738911758.USD","MRK","SG9999014898.SGD","LU1923622614.USD","LU2168564495.EUR","LU0072461881.USD","LU2462157665.USD","LU0070302665.USD","LU1066053197.SGD","BK7501","LU0472753341.HKD","LU0158827781.USD","GB00BDT5M118.USD","TBXU","LU0114720955.EUR","LU1061106388.HKD","LU2271345857.HKD","LU0942090050.USD","LU1064131342.USD","IE00B894F039.SGD","LU0289739343.SGD","LU0006306889.USD","TRUH","IE0001KFT4U8.USD","LU0965509010.AUD","OZEM","LU2433249047.HKD","LU2129689431.USD","CURE","GDOC","LU0345770308.USD","BK4533","LU1551013342.USD","LU1988902786.USD","LU0133085943.USD","IE00B7KXQ091.USD","LU1670628061.USD","LU2461242641.AUD","SG9999015945.SGD","LU1979441026.SGD","LU2237438978.USD","BK4516","IE00B4R5TH58.HKD","IE0000B7K699.USD","NVOH","BK4578","LU0320765059.SGD","LU0265550946.USD","SG9999018857.SGD","WDNA","BK4581","BK4007","04332","LU0672654240.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658398169","title":"Vertex Pharma股價上漲，因競爭對手的遺傳性疾病藥物研發遭遇挫折","url":"https://stock-news.laohu8.com/highlight/detail?id=2658398169","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658398169?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 20:36","pubTimestamp":1786365394,"startTime":"0","endTime":"0","summary":"BUZZ-Vertex Pharma股价上涨，因竞争对手的遗传性疾病药物研发遭遇挫折8月10日-** 制药公司Vertex Pharmaceuticals（VRTX.O）的股价在盘前交易中上涨7.65%，至534美元** Sionna Therapeutics（SION.O） (link) 表示，由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标，公司将终止该药物的研发** ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4T4470W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU0061475181.USD","IE00B4R5TH58.HKD","IE0002270589.USD","LU1035775433.USD","LU0079474960.USD","TBXU","IE00B894F039.SGD","LU0058720904.USD","BK4588","LU0109394709.USD","IE00BZ9MQY76.HKD","LU2462157665.USD","PBE","LU2456880835.USD","SG9999013999.USD","BK4567","BBH","SG9999001176.SGD","IE00B19Z3B42.SGD","IBB","LU1674673428.USD","LU2324357040.USD","VRTX","IE00B19Z9P08.USD","GNMX","BK4533","IE00B2B36J28.USD","LU2237438978.USD","LU0320765992.SGD","LU1778281490.HKD","IE0002141913.USD","IDNA","BK4532","LU0256863811.USD","LU1674673691.USD","LU1069344957.HKD","BIB","SGXZ57979304.SGD","SG9999001176.USD","LU2236285917.USD","LU0889565916.HKD","LU0234570918.USD","LU0823416689.USD","IE00B19Z3581.USD","IBBQ","LU0417517546.SGD","LU1093756168.USD","SION","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658535936","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑 跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2658535936","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658535936?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363243,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836820982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836820982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["JDOC","BK4144","PJP","MEDI","RSPH","FHLC","TMED","IHE","BBH","PBPH","GSKH","FXH","GLP","APXH","TRUH","BBP","BME","BK4590","IYH","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189831237","title":"百濟神州獲Revolution Medicines四大資產在選定亞洲市場的獨家授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1189831237","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189831237?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 18:05","pubTimestamp":1786356339,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）宣布，已获得Revolution Medicines, Inc.旗下四项核心资产在特定亚洲市场的独家权利。这一战略合作，标志着百济神州在亚洲关键区域的布局进一步深化。\n依据协议，百济神州将独家享有Revolution Medicines这四款创新药物在部分亚洲国家和地区的开发、商业化权益。此举不仅丰富了百济神州的肿瘤产品管线，也为其在亚洲市场的竞争力增添了强劲动力。交易的财务细节尚未披露，但市场分析人士普遍认为，此举对双方而言都是互利共赢的明智选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","RVMD","IE0009355771.USD","BK0239","IDNA","LU0320765992.SGD","IE00BJT1NW94.SGD","BK4139","CANC","IE0009354923.USD","688235","LU0889565916.HKD","PTH","BBH","IE0002141913.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":198,"code":"91000000","status":"200"}]}}